
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of Phio Pharmaceuticals in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Keller now expects that the company will post earnings of ($1.41) per share for the year, up from their previous forecast of ($1.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.35) EPS and FY2027 earnings at ($0.73) EPS.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $14.00.
Read Our Latest Analysis on Phio Pharmaceuticals
Phio Pharmaceuticals Trading Down 4.7%
Phio Pharmaceuticals stock opened at $0.72 on Wednesday. The stock has a 50-day moving average of $0.93 and a two-hundred day moving average of $1.07. Phio Pharmaceuticals has a one year low of $0.70 and a one year high of $1.88.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.36).
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals is a clinical-stage biotechnology company developing treatments based on its INTASYL platform, a technology for delivering RNA interference compounds into cells to reduce the activity of selected genes. The company focuses on potential therapies for cancer, particularly approaches intended to strengthen the body’s immune response to tumors. Its pipeline includes candidates designed to target genes involved in immune regulation and tumor biology. These investigational treatments are being developed for solid tumors; they are not approved for commercial use.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
